Option Care Health, Inc.: insider trades · United States · SEC (Form 4)

About Option Care Health, Inc.

Option Care Health, Inc. (ticker OPCH) is listed on the NASDAQ market in the United States and is widely positioned as the largest independent provider of home and alternate site infusion services. Headquartered in Bannockburn, Illinois, the company operates across all 50 U.S. states and combines pharmacy operations, clinical coordination, nursing support, and specialized care delivery for patients with acute and chronic conditions. For international investors, the business sits at the intersection of healthcare services, specialty distribution, and outpatient care infrastructure. The company’s current structure reflects a consolidation story. Option Care Health was formed in August 2019 through the merger of legacy Option Care and BioScrip, creating a national platform with greater scale, broader geographic reach, and a stronger ability to negotiate with payers, healthcare systems, physicians, and biopharmaceutical manufacturers. While the brand is relatively recent in its present form, management emphasizes more than 45 years of operational experience in infusion therapy and related care services. The group today reports over 8,000 employees, including more than 5,000 clinicians, underlining the labor-intensive and clinically driven nature of the model. Its core business is home and alternate site infusion therapy. That includes the preparation and dispensing of infusion drugs, patient education, nursing administration, adherence and care management, and logistical support for complex therapies delivered outside the hospital setting. This model is especially relevant for chronic diseases, post-acute treatment, and higher-complexity therapies that can be safely shifted into lower-cost environments. The company also highlights growing involvement in rare, orphan, and other novel therapies, which can carry attractive growth characteristics but require strong clinical execution and regulatory discipline. From a competitive standpoint, Option Care Health benefits from national scale, a broad referral network, established relationships with payers and manufacturers, and the ability to support a wide array of therapy classes. Management has also been investing in technology, analytics, automation, machine learning, and artificial intelligence to improve reliability, efficiency, onboarding speed, and cash collection. This is important in a business where operational excellence and reimbursement execution can be as decisive as clinical capability. Recent developments have reinforced the company’s strategic focus. In 2024, management described the year as one of resilience amid hurricanes, supplier shortages, and a cyberattack affecting a major healthcare claims processor, while still delivering growth and cash generation. In January 2025, Option Care Health completed the acquisition of Intramed Plus, expanding its infusion pharmacy and clinic footprint in South Carolina. More recently, the company reported continued quarterly growth in 2025 and 2026, alongside share repurchases and an expanded revolving credit facility, suggesting a business that remains active both operationally and financially. For equity investors monitoring SEC Form 4 insider transactions, OPCH offers exposure to a U.S.-listed healthcare platform with defensive demand characteristics and ongoing consolidation optionality.